One dose of LSD provides weeks of anxiety relief, study finds
UC expert comments on new study to USA Today
The University of Cincinnati's Jeffrey Strawn was featured in a USA Today article commenting on a new study that found a pharmaceutical version of the psychedelic LSD might help alleviate anxiety symptoms for up to three months.
Study results were published Sept. 4 in the journal JAMA. The Phase 2, randomized clinical trial evaluated MM120, a pharmaceutical version of LSD, or lysergide D-tartrate, in 198 adults who had generalized anxiety disorder. After 12 weeks, anxiety symptoms improved in 65% of adults who took a single, 100-mg dose of the drug compared to 30.8% who took a placebo.
The study reported a "remission" rate of 47.5% among adults 12 weeks after taking a single dose compared to 20% who took a placebo. More than nine in 10 people on the 100-mg dose experience hallucinations, with other common side effects including nausea and headaches.
Strawn was not involved in the study, but oversees a clinical trial site for one of MM120's current Phase 3 studies. He said the study is "really important," as anxiety treatments have "really not significantly changed in decades."
"This is a disorder where often we are frustrated as clinicians marching through multiple treatments that don't work or produce side effects," Strawn, MD, professor in the Department of Psychiatry and Behavioral Neuroscience in UC’s College of Medicine and a UC Health child and adolescent psychiatrist, told USA Today. "Also, our patients are frustrated."
Featured photo at top of Dr. Strawn. Photo/Colleen Kelley/UC Marketing + Brand.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.